This Could Change TRT Forever: How 3-AD Might Eliminate the Testosterone Crash

By: Marc Lobliner, IFBB Pro

Anyone on TRT knows the story. You take your shot, feel great for a few days, and then the crash hits. Energy drops, motivation fades, and mood swings creep in as hormone levels fall. For years that has been the cycle—until now.

Recent lab data from an independent subject experimenting with 3 AD alongside TRT is showing results that could completely reshape how we understand testosterone therapy.

This is not peer-reviewed science, but the findings are remarkably consistent and too compelling to ignore.

What the Data Shows

The subject took 125 milligrams of TRT while supplementing with 100 milligrams of 3 AD daily. Blood was drawn the next day to capture the post-injection peak. Five days later, testosterone levels had declined only 4.6 percent.

Normally, levels would drop by 50 percent or more over that same period when using TRT alone.

After the subject stopped 3 AD but kept the same 125 milligram TRT dose, the numbers reverted to normal behavior—a 55 percent decline in five days.

That single variable, 3 AD, appears to extend testosterone’s effective half-life by roughly ten times. Based on decay modeling, the half-life works out to about 58 days, with the rate of decline increasing slightly after day 7 to 10. The shape of the curve is completely different from standard TRT patterns.

The Hematocrit Effect

Another notable observation was a one-percent drop in hematocrit between Monday and Friday, even though total testosterone remained nearly identical. With TRT alone, hematocrit typically tracks alongside testosterone fluctuations. The steadier values here suggest that 3 AD might be slowing metabolic clearance and reducing hormonal volatility.

In other words, testosterone levels not only stay elevated longer but do so more smoothly. Energy, focus, and general wellbeing remain consistent rather than swinging between peaks and valleys.

Practical Takeaways

Based on this data, injections every fourteen days while using 3 AD seem ideal. The extended half-life reduces the need for frequent dosing and eliminates the sharp post-shot crash.

The advantage is not only in maintaining higher total testosterone but in maintaining stability. The line between injections is no longer a steep drop; it becomes a controlled glide.

Possible Mechanisms

Researchers are still theorizing how this happens. 3 AD may alter testosterone metabolism, slow enzymatic breakdown, or affect hormone binding and clearance pathways in the liver or kidneys. It could also improve utilization efficiency, allowing the body to maintain active testosterone for longer.

Whatever the mechanism, the end result is clear: testosterone levels remain elevated for an extended period and decline far more gradually.

The Caveats

This data is preliminary and not peer reviewed. 3 AD is not FDA-approved for medical use, and combining it with TRT should be done only under medical supervision. Long-term safety, lipid effects, and impacts on organ health still need study.

Anyone considering this combination should monitor hematocrit, lipids, and liver enzymes carefully and discuss the protocol with a qualified physician.

Final Thoughts

The goal of TRT has always been consistency. Fewer crashes, more stable performance, and better overall health. The early data on 3 AD suggests that might finally be achievable.

With slower declines, extended half-life, steadier mood, and more predictable lab markers, this could represent a major advancement in hormone optimization.

If future research confirms what this early case indicates, 3 AD might completely change the way we approach testosterone replacement therapy.